Evidence map›Paper›PMID 39335665›Full record

ArticleBiomedicines2024

Targeting CD47 and Angiogenesis Demonstrates Effective Anti-Tumor Effect in Bladder Cancer.

Xiting Huang, Qian Wang, Yanyang Nan, Xuyao Zhang, Ke Xu, Dianwen Ju, Weihong Ding

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiting HuangDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Qian WangDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Yanyang NanDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Xuyao ZhangDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.ORCID 0000-0003-1654-5550
Ke XuDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Road, Shanghai 200040, China.
Dianwen JuDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmacy, Fudan University, Shanghai 201203, China.
Weihong DingDepartment of Urology, Huashan Hospital, Fudan University, 12 Central Urumqi Road, Shanghai 200040, China.

Funding

Medical Engineering Jiont Fund of Fudan University yg2022-30National Key Research and Development Program of China 2023YFC3404000National Key Research and Development Program of China 2023YFC3503403National Key Research and Development Program of China 2023YFC3606600National Natural Science Foundation of China 32200745National Natural Science Foundation of China 82073752National Natural Science Foundation of China 82371781Shanghai Sailing Program 21YF1401900
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

angiogenesisbladder cancerCD47 blockade therapycombinational therapyinnate immunity

Identifiers

PMID39335665
PMCPMC11430664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.